Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma

por Nelson, Luke J, Castro, Kyleen E, Xu, Binzhi, Li, Junyi, Dinh, Nguyen B, Thompson, Jordan M, Woytash, Jordan, Kipp, Kevin R, Razorenova, Olga V
Publicado 2022